ADC Therapeutics Financials
| ADCT Stock | USD 1.61 0.09 5.29% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.46 | 5.72 |
|
|
Investors should never underestimate ADC Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor ADC Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in ADC Therapeutics SA.
Net Income |
|
ADC | Select Account or Indicator |
Understanding current and past ADC Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of ADC Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in ADC Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in ADC Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ADC Therapeutics SA. Check ADC Therapeutics' Beneish M Score to see the likelihood of ADC Therapeutics' management manipulating its earnings.
ADC Therapeutics Stock Summary
ADC Therapeutics competes with Passage Bio, Black Diamond, Alector, Century Therapeutics, and Generation Bio. ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. ADC Therapeutics operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 312 people.Specialization | Information Technology, Technology Hardware & Equipment |
| Instrument | USA Stock View All |
| Exchange | New York Stock Exchange |
| ISIN | CH0499880968 |
| CUSIP | H0036K147 |
| Location | Switzerland |
| Business Address | BiopOle, Epalinges, Switzerland, |
| Sector | Communications Equipment |
| Industry | Information Technology |
| Benchmark | Dow Jones Industrial |
| Website | www.adctherapeutics.com |
| Phone | 41 21 653 02 00 |
| Currency | USD - US Dollar |
ADC Therapeutics Key Financial Ratios
| Return On Equity | -7.06 | ||||
| Profit Margin | (3.00) % | ||||
| Operating Margin | (1.93) % | ||||
| Price To Sales | 2.20 X | ||||
| Revenue | 69.56 M |
ADC Therapeutics Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 513.7M | 618.0M | 529.2M | 354.8M | 408.0M | 375.5M | |
| Other Current Liab | 29.4M | 49.5M | 68.5M | 50.6M | 58.2M | 33.5M | |
| Net Debt | (397.3M) | (364.8M) | (209.1M) | (154.2M) | (138.8M) | (145.7M) | |
| Retained Earnings | (694.9M) | (924.9M) | (1.1B) | (1.3B) | (1.2B) | (1.1B) | |
| Accounts Payable | 5.3M | 12.1M | 12.4M | 15.6M | 17.9M | 9.0M | |
| Cash | 439.2M | 466.5M | 326.4M | 278.6M | 320.4M | 298.6M | |
| Net Receivables | 3.1M | 30.2M | 73.0M | 25.2M | 29.0M | 19.8M | |
| Other Current Assets | 11.3M | 17.3M | 23.5M | 16.3M | 18.8M | 9.9M | |
| Total Liab | 178.2M | 451.9M | 440.4M | 503.0M | 578.5M | 607.4M | |
| Total Current Assets | 450.5M | 525.2M | 446.0M | 336.3M | 386.7M | 335.4M | |
| Intangible Assets | 8.4M | 10.2M | 13.6M | 14.4M | 16.5M | 9.7M | |
| Common Stock | 4.4M | 6.3M | 6.4M | 7.3M | 8.4M | 4.5M | |
| Other Liab | 2.7M | 100.5M | 65.1M | 25.3M | 29.1M | 36.3M | |
| Net Tangible Assets | 102.7M | 325.3M | 153.1M | 75.3M | 67.8M | 64.4M | |
| Other Assets | 397K | 27.4M | 28.6M | 1.0 | 1.15 | 1.09 | |
| Inventory | 6.5M | 11.1M | 18.6M | 16.2M | 18.6M | 19.5M | |
| Net Invested Capital | 447.1M | 297.8M | 198.4M | (35.5M) | (32.0M) | (30.4M) | |
| Net Working Capital | 410.0M | 451.2M | 347.1M | 268.6M | 308.9M | 305.5M | |
| Capital Stock | 4.4M | 6.3M | 6.4M | 7.3M | 8.4M | 5.9M | |
| Short Term Debt | 5.6M | 8.6M | 1.1M | 1.5M | 1.3M | 1.3M |
ADC Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what ADC Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Tax Provision | 327K | (21.5M) | 1.1M | (3.0M) | (2.7M) | (2.8M) | |
| Net Interest Income | (4.1M) | (18.3M) | (19.0M) | (39.6M) | (35.6M) | (33.8M) | |
| Interest Income | 832K | 66K | 18.0M | 6.6M | 7.6M | 5.0M | |
| Interest Expense | 4.9M | 18.3M | 36.9M | 46.3M | 53.3M | 55.9M | |
| Total Revenue | 0.0 | 33.9M | 209.9M | 69.6M | 80.0M | 50.1M | |
| Gross Profit | (2.0M) | 32.5M | 205.3M | 67.0M | 77.1M | 80.9M | |
| Operating Income | (219.3M) | (261.7M) | (123.6M) | (166.0M) | (149.4M) | (156.9M) | |
| Ebit | (221.2M) | (226.3M) | (110.4M) | (150.0M) | (135.0M) | (141.8M) | |
| Research Development | 142.0M | 158.0M | 187.9M | 127.1M | 146.2M | 145.6M | |
| Ebitda | (219.3M) | (223.7M) | (108.1M) | (146.8M) | (132.1M) | (138.7M) | |
| Cost Of Revenue | 2.0M | 1.4M | 4.6M | 2.5M | 2.3M | 2.2M | |
| Income Before Tax | (246.0M) | (251.5M) | (154.7M) | (195.4M) | (175.9M) | (184.7M) | |
| Net Income | (246.3M) | (230.0M) | (155.8M) | (240.1M) | (216.0M) | (226.9M) | |
| Income Tax Expense | 327K | (21.5M) | 1.1M | 39.1M | 45.0M | 47.2M |
ADC Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ADC Therapeutics's current stock value. Our valuation model uses many indicators to compare ADC Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ADC Therapeutics competition to find correlations between indicators driving ADC Therapeutics's intrinsic value. More Info.ADC Therapeutics SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, ADC Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value ADC Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ADC Therapeutics Systematic Risk
ADC Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ADC Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on ADC Therapeutics correlated with the market. If Beta is less than 0 ADC Therapeutics generally moves in the opposite direction as compared to the market. If ADC Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ADC Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ADC Therapeutics is generally in the same direction as the market. If Beta > 1 ADC Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in ADC Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ADC Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of ADC Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
ADC Therapeutics March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ADC Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ADC Therapeutics SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of ADC Therapeutics SA based on widely used predictive technical indicators. In general, we focus on analyzing ADC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ADC Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 21.05 | |||
| Value At Risk | (7.55) | |||
| Potential Upside | 8.78 |
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.